BOUDRY, Switzerland--(BUSINESS WIRE)--Feb. 27, 2013--
EURORDIS (The European Organisation for Rare Diseases) announced today
that Celgene Corporation (NASDAQ:CELG) has been awarded the prestigious
EURORDIS Company Award for excellence in the field of rare diseases. The
award, presented just in advance of Rare Diseases Day, February 28,
recognises Celgene’s established track record in the area of orphan
diseases, with multiple orphan designations and approved
disease-altering therapies addressing patient needs and a robust
pipeline of innovative compounds under development. The award also
acknowledges Celgene’s efforts to engage in quality dialogue and
partnership with EURORDIS and patient groups in relevant disease areas.
The EURORDIS Awards recognise outstanding patients' advocacy groups,
volunteers, scientists, companies, media, and policy makers who have
contributed to reducing the impact of rare diseases on people's lives.
The winners of the awards are selected from more than 100 nominations
received from EURORDIS members including rare disease patient advocacy
groups across Europe, volunteers and staff.
With 17 orphan drug designations* and four approved orphan drug
indications granted by the European Medicines Agency (EMA), Celgene
holds a leading position among companies developing therapies for rare
diseases1. The Celgene pipeline currently includes active
clinical trial programs in 45 rare conditions, with Celgene investing
31% of its annual revenues into ongoing research and development
efforts. As part of these efforts, there is a clear commitment from the
company to continue extensive research in the area of rare diseases,
which is the foundation on which the company was built.
“We are honored to receive the EURORDIS Company Award for our work in
rare diseases, which is a testament to the strong partnerships we have
throughout Europe with the people focused on treatment options for some
of the most difficult-to-study and difficult-to-treat conditions,” said
Stefano Portolano, M.D., Vice President, Hematology Europe at Celgene,
who accepted the award on behalf of Celgene. “In the nearly 13 years
since the Orphan Drug Regulation was enacted, there has been growing
recognition of the need for treatments for rare diseases that help
patients live longer and higher quality lives. Celgene is proud to be
recognized for its contributions in this area, along with the important
work by groups like EURORDIS.”
A recent demonstration of Celgene’s ongoing efforts to drive clinical
advances and provide new therapeutic options for patients with rare
diseases was the announcement on 8 February 2013 of the U.S. Food and
Drug Administration (FDA) approval of pomalidomide for patients with
multiple myeloma, who received at least two prior therapies including
lenalidomide and bortezomib and have demonstrated disease progression on
or within 60 days of completion of the last therapy. Pomalidomide is
currently under review by the European regulatory authority, the
European Medicines Authority (EMA).
Yann Le Cam, Chief Executive Officer, EURORDIS, commented; “We are
honoured to acknowledge the commitment and achievements of this year’s
recipients of the EURORDIS Awards on the occasion of Rare Disease Day
2013. Each of this year’s ten awardees contributes in their own unique
way toward fostering the goals of cooperation embodied in this year’s
Rare Disease Day slogan: ‘Rare Disorders without Borders’. We are proud
that the rare disease community is becoming a model for
multi-stakeholder partnership and international collaboration as well as
for solidarity and unity throughout Europe.”
Orphan diseases are rare and often debilitating conditions, defined in
the European Union as affecting no more than five per 10,000 people.
There are between 5,000 and 8,000 different rare diseases affecting an
estimated 29 million people in the EU.
* Special regulatory status, granted to a product developed to treat
NOTES TO EDITORS
Celgene International Sàrl, located in Boudry, in the Canton of
Neuchâtel, Switzerland, is a wholly owned subsidiary and international
headquarters of Celgene Corporation.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global pharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative therapies for
the treatment of cancer and inflammatory diseases through gene and
protein regulation. For more information, please visit the Company's
website at www.celgene.com.
Celgene has been operating in Europe since 2006 and is currently present
in 22 EU countries. By utilizing the latest advances in molecular and
cellular research to develop novel therapies that target the mechanisms
of disease at their source, Celgene is driving clinical advances in
debilitating diseases for patients with the biggest unmet medical needs.
Current Celgene portfolio covers a wide range of rare conditions
including: acute myeloid leukaemia, chronic lymphocytic leukaemia,
cutaneous T-cell lymphoma, multiple myeloma, myelodysplastic syndromes
and primary myelofibrosis, Bechet’s disease to name but a few.
About the EURORDIS Awards 2013
EURORDIS is a leading International Non-Governmental Organisation (INGO)
and is recognised as the largest European patient organisation in the
field of rare diseases. The EURORDIS Awards recognise outstanding
patients' advocacy groups, volunteers, scientists, companies, media, and
policy makers who have contributed - directly or indirectly - to
reducing the impact of rare diseases on people's lives.
1. Community Register of Orphan Medicinal Products for Human Use;
accessed 22 October 2012
+41 32 729 62 36